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ABSTRACT The human body plays host to a wide variety of microbes, commensal and pathogenic. In addition to interacting with
their host, different microbes, such as bacteria and viruses, interact with each other, sometimes in ways that exacerbate disease.
In particular, gene expression of a number of viruses, including Kaposi’s sarcoma-associated herpesvirus (KSHV), Epstein-Barr
virus (EBV), and human immunodeficiency virus (HIV), is known to be regulated by epigenetic modifications induced by bacte-
ria. These viruses establish latent infection in their host cells and can be reactivated by bacterial products. Viral reactivation has
been suggested to contribute to periodontal disease and AIDS. In addition, bacterium-virus interactions may play a role in can-
cers, such as Kaposi’s sarcoma, gastric cancer, and head and neck cancer. It is important to consider the effects of coexisting bac-
terial infections when studying viral diseases in vivo.
Epigenetics refers to biochemical modifications of chromatinthat do not change the sequence but regulate gene expression
and may be inherited. Several different types of epigenetic modi-
fications exist, such as DNA methylation, histone modification,
and nucleosome positioning, and they can regulate a variety of
processes, including transcription and protein binding to DNA.
DNA methylation occurs mostly in regions containing a high fre-
quency of CpG dinucleotides, called CpG islands. In most cases,
DNA methylation is associated with gene silencing and is medi-
ated by a family of enzymes called DNA methyltransferases (DN-
MTs). DNA is wrapped around eight-member histone complexes
called nucleosomes. Histones have unstructured N-terminal tails,
which undergo posttranslational modifications, including acety-
lation, methylation, phosphorylation, ubiquitination, and SU-
MOylation, at certain positions. There are many enzymes that
write or erase these modifications: a few examples are methyl-
transferases, demethylases, histone acetyltransferases (HATs),
and histone deacetylases (HDACs). Some histone marks, such as
H3K27ac and H3K9ac are associated with actively transcribed
genes, whereas others, like H3K27me3 and H4K27me3, keep
genes in an inactive state. In addition, the position of nucleosomes
affects transcription by preventing transcription factors or the
polymerase complex from binding or inhibiting elongation. There
are several complexes that can remove or shift nucleosomes, such
as SWI/SNF (1). Epigenetic features have been shown to be pre-
dictive of genome-wide gene expression (2).
Epigenetic modifications regulating gene expression can occur
on both human and viral genomes. HIV and herpesviruses, in-
cluding Kaposi’s sarcoma-associated herpesvirus (KSHV) and
Epstein-Barr virus (EBV), establish lifelong latent infections in
their host cells. KSHV, EBV, herpes simplex virus 1 (HSV-1), and
HIV latency and reactivation are controlled by epigenetic modifi-
cations (3–8). Viruses and bacteria have developed diverse mech-
anisms to directly affect host cell epigenetics, driving pathogenesis
and oncogenesis (3, 9–14). This review will focus on bacterium-
promoted epigenetic modifications on viral genomes that regulate
the switch between latency and active viral replication and exam-
ples of combined bacterial and viral disease.
BACTERIA ACTIVATE VIRUSES VIA EPIGENETIC CHANGES:
MECHANISMS
Kaposi’s sarcoma: P. gingivitis and KSHV. In the oral cavity, ac-
tive viral replication and shedding occur, indicating that viruses
do not remain latent. Kaposi’s sarcoma-associated herpesvirus
(KSHV) is the causative agent of Kaposi’s sarcoma, an AIDS-
defining tumor that can be found in the mouth (15, 16). The
incidence of oral lesions associated with HIV has decreased since
the introduction of highly active antiretroviral therapy (HAART);
however, they still cause significant morbidity and are indicative
of progression to AIDS (17–19). The transition to viral reactiva-
tion or oncogene expression requires epigenetic reprogramming
(Fig. 1), illustrated by the hypermethylation of active KSHV pro-
moters (20). Epigenetic reprogramming of both the host and viral
genomes can be initiated by oral bacteria. Bacterial infection leads
lymphoid cells, which may harbor inactive viruses (e.g., EBV and
KSHV), to be recruited to the oral epithelium. This places virus-
infected cells and bacteria and their end products in close prox-
imity. Bacteria are present in the oral cavity in abundance, with 20
billion microbes present in our mouths at any given time (21).
One of several bacteria commonly found in the mouth is Por-
phyromonas gingivalis, a widely studied bacterium in the phylum
Bacteroidetes. The bacteria colonize in a highly site-specific fash-
ion, so the bacterial load can be extremely high at a very discrete
site. P. gingivalis secretes a number of products, including lipo-
polysaccharide (LPS), gingipains, outer membrane vesicles
(OMVs), and short-chain fatty acids (SCFAs) (22–26). Within
gingival pockets, accumulation of SCFAs, including butyrate and
LPS, can be detected in association with P. gingivalis infection
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(27). Bacterial butyric acid levels can be up to 20 mM within the
gingival pocket (25, 28, 29). Our group and others have suggested
that products secreted by P. gingivalis, including butyrate, induce
acetylation of histones within neighboring cells (25, 30, 31).
P. gingivalis metabolites, but not those of Gram-positive or-
ganisms, were able to enhance KSHV replication. To further ex-
plore the mechanism behind these changes, BCBL-1 cells, which
are latently infected with KSHV, were treated with Fusobacterium
nucleatum or P. gingivalis culture medium and exposed to specific
inhibitors of signal transduction pathways. We determined that
bacterium-mediated induction of lytic KSHV infection was not
prevented by inhibition of phosphatidylinositol 3-kinase (PI3K)
or protein kinase C (PKC) but was significantly reduced by inhi-
bition of the p38 mitogen-activated protein kinase (MAPK) path-
way. Bacterium-mediated KSHV reactivation coincided with in-
creased global acetylation of H3 and H4, suggesting the bacterial
supernatant contains HDAC inhibition properties. Furthermore,
p38 inhibition by multiple inhibitors prevented H3 hyperacetyla-
tion and subsequent viral reactivation (31). HDAC inhibition is
also critical to the antiviral interferon response (32, 33). The poly-
microbial environment may potentiate viral reactivation by de-
creasing the innate antiviral response and enhancing viral patho-
genesis.
Periodontitis: P. gingivalis and herpesviruses. Studies linking
bacterium-induced epigenetic modifications on viral genomes to
human disease are emerging. Periodontitis is highly prevalent in
humans, but its etiology is still poorly understood (34). While
periodontitis is primarily associated with infection by pathogenic
bacteria, such as Actinobacillus actinomycetemcomitans and P. gin-
givalis, herpesviruses have also been implicated (35–37). Multiple
studies have shown that in patients with periodontal and end-
odontic disease, herpes group viruses, including human cytomeg-
alovirus (HCMV), EBV, and HSV-1, are readily detected and are
associated with the presence of bacteria (38–43). Levels of viral
detection were lower in those with less gum disease (44). More-
over, a viral contribution helps explain some symptoms of peri-
odontal disease, such as remission, bilateral symmetry, and why
periodontitis often only affects a few teeth, with neighboring teeth
exhibiting much less tissue loss (35). Bacterial and viral coinfec-
tion was also detected in two-thirds of acute apical abscesses, al-
though the role of the viruses or any interaction between the
pathogens in this form of periodontitis is unclear (45). Epigenetic
modification of herpesviruses by P. gingivalis (discussed below)
helps explain the link between viruses and bacteria in the patho-
genesis of periodontitis.
Bacterium-induced HDAC inhibition leading to viral reactiva-
tion has been observed for EBV. One protein controlling EBV
reactivation is ZEBRA, a lytic gene transactivator and the product
of the BZLF1 gene. In Daudi cells latently infected with EBV, ZE-
BRA expression was increased by P. gingivalis spent medium, trig-
gering viral reactivation. The virulence factors LPS, fimbriae, or
gingipains alone had no effect on ZEBRA expression. Among the
various SCFAs produced by P. gingivalis, including butyric, isobu-
tyric, propionic, acetic, and valeric acids, only butyric acid treat-
ment led to induction of ZEBRA. After treatment with P. gingivalis
culture supernatant or butyric acid, binding of H3ac, a mark of
active chromatin, to the BZLF1 promoter increased, while binding
of HDACS 1, 2, and 7 decreased. ZEBRA expression also requires
chromatin remodeling, as treatment with novobiocin, a topo-
isomerase II inhibitor, blocks P. gingivalis-induced ZEBRA pro-
duction (46, 47).
Butyrate is an HDAC inhibitor and has been implicated in the
reactivation of HIV and EBV (46, 48, 49). However, butyrate may
not be the only P. gingivalis product involved in epigenetic regu-
lation, as differences were found between cellular epigenetic
changes induced by P. gingivalis and F. nucleatum, another Bacte-
roidete anaerobe whose primary end product is butyrate. While
global H3K4me3 decreased with P. gingivalis, H3K4me3 did not
decrease in gingival cells incubated with F. nucleatum (50). In
addition, P. gingivalis produces LPS, and LPS-induced Toll-like
receptor (TLR) signaling leads to widespread changes in the epi-
genetic profiles of TLR-responsive genes (51, 52). Gingipains,
OMVs, and other SCFAs, such as propionic and isobutyric acids,
are also produced by P. gingivalis and may affect epigenetics (23–
26).
P. gingivalis also elicits changes in the expression of enzymes
that regulate epigenetics, which could lead to global changes in
epigenetic profiles for both the virus and the host. For example,
exposure of keratinocytes to P. gingivalis LPS downregulated ex-
pression of DNMT1, HDAC1, and HDAC2, all enzymes that pro-
mote epigenetic events (53). P. gingivalis uses epigenetic means to
modulate the immunoregulatory proteins -defensin2 and
CCL20 and increases promoter methylation for a number of
growth control and inflammatory genes (50). In addition, oral
bacteria associated with periodontal disease, such as P. gingivalis,
FIG 1 Epigenetic modifications to viral promoters can promote viral production or oncogenesis. Activating epigenetic marks on tumor virus promoters can
stimulate the transcription of viral oncogenes, driving cellular transformation, or lead to reactivation of a latent virus and production of new virions.
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induce oxidative stress, a process central to epigenetic modifica-
tion (54, 55).
HNSCC: periodontitis-associated bacteria and HPV. In ad-
dition to tobacco and alcohol use, periodontitis has been associ-
ated with oral cancer and premalignant lesions, which in turn are
associated with human papillomavirus (HPV). One study found
that patients with periodontal disease have an increased risk for
oral cancer and premalignant lesions, but only for current smok-
ers (56). A later study from the same group looking at head and
neck squamous cell carcinoma (HNSCC) found a significantly
increased risk of cancer in patients with alveolar bone loss. An
increased risk was found even for nonsmokers with chronic peri-
odontitis, but smokers had a higher risk. In addition, patients with
periodontitis were significantly more likely to have poorly differ-
entiated HNSCC (57). HPV, particularly subtype 16, has been
associated with HNSCC, as well as cervical cancer (58). In one
study, approximately 40% of HNSCCs were positive for HPV16,
and alveolar bone loss increased the odds of HPV-positive tumor
status, with a stronger association in oropharyngeal SCC than in
oral or laryngeal SCC (59). In base of tongue cancer, HPV16 was
found in 70% of tumors, and the patients with HPV16-positive
tumors had significantly worse periodontitis than patients with
HPV-negative tumors, as measured by alveolar bone loss (60). In
addition, it has been suggested that streptococci in the oral cavity
promote the development of HPV-associated HNSCC through
stimulation of the host inflammatory response and production of
carcinogenic metabolites, such as acetaldehyde (61).
The bacterial pathogens that cause periodontal disease are
known to cause epigenetic modifications to the genomes of EBV,
KSHV, and HIV and may modify other viral genomes as well.
Another example of a virus that may be affected bacterial epige-
netic modulation is HPV16. HPV16 transcription, mediated by
the E2 protein, is reduced by CpG methylation of the E2 binding
sites in cervical epithelial cells (62). HPV hypomethylation is as-
sociated with cervical cancer progression, as progressively less
methylation was seen in patients with carcinoma than in patients
with precancerous lesions and asymptomatic infection (63). Fur-
thermore, cell lines derived from HPV-associated HNSCCs have
increased DNMT3A expression and cellular DNA methylation in
regions containing genes and LINE 1 elements compared to cell
lines from HPV-negative HNSCCs (64). Taken together, these
studies suggest an additional link between bacteria and HPV-
associated cancer.
HIV and AIDS: oral, gut, and vaginal bacteria. Several loca-
tions in the body are colonized by many microbes that can influ-
ence each other as well as their host, sometimes leading to disease.
Not only can interactions occur between pathogenic bacteria and
viruses, but opportunistic or commensal microbes may also come
into play, particularly in immunosuppressed individuals (Fig. 2).
It has been suggested that periodontal disease (P. gingivalis) and
opportunistic bacteria that are associated with HIV immune sup-
pression may in turn contribute to AIDS progression by produc-
ing butyric acid and leading to HIV reactivation through HDAC
inhibition (65, 66). Furthermore, AIDS-related immune suppres-
sion can lead to an increase in opportunistic bacterial load, which
could further reactivate HIV, hastening AIDS progression (65)
(Fig. 2). The gut is another major site of polymicrobial coloniza-
tion and infection. In early stages of HIV infection, the composi-
tion of the gut microbiota changes, and increased inflammation in
the gastrointestinal (GI) tract leads to damage of the mucosal bar-
rier (67). Breakdown of the intestinal barrier allows microbial LPS
to enter the blood and results in chronic immune activation, a
commonly observed feature of HIV infection and a contributor to
the progression to AIDS (68, 69). In the vagina, increased risk of
HIV acquisition, transmission, and HIV reactivation have been
linked to bacterial vaginosis (70–74). Recent studies indicate the
importance of the microbiota in multiple body compartments to
the development of AIDS.
In the mouth, P. gingivalis-induced histone modifications have
been shown to increase transcription of both integrated and non-
integrated HIV (49, 75). Gene expression and replication of non-
integrating HIV-1 were increased in vitro upon exposure to his-
tone deacetylase inhibitors in the form of various short-chain fatty
acids (SCFAs) known to be endogenously produced by normal
microbial gut flora. The increased expression of integrated HIV
was attributed particularly to butyric acid produced by the bacte-
ria, not any virulence factor (LPS, fimbriae, or gingipain) or other
SCFA (75). Integrated HIV is silenced by a number of repressive
epigenetic modifications, including HDAC recruitment, methyl-
ated H3 (H3K9me3, H3K27me3, and H3K9me2), and binding of
Polycomb Repressive Complex 2 members (7). P. gingivalis and
butyric acid were found to increase H3 and H4 acetylation and
binding of polymerase II to the HIV long terminal repeat (LTR).
These treatments also decreased binding of two repressors of gene
expression: HDAC1 and AP-4. P. gingivalis-mediated HIV tran-
scription was diminished by novobiocin, a topoisomerase II in-
hibitor, indicating dependence on chromatin remodeling (75).
HIV gene expression is stimulated by P. gingivalis, and epigenetic
changes are critical.
In addition to the oral cavity, several studies have focused on
HIV reactivation in the gut and vagina. Gene expression and rep-
lication of nonintegrated HIV were notably increased in vitro
upon exposure to various short-chain fatty acids (SCFAs) endog-
enously produced by gut bacteria (49). HIV can be reactivated by
supernatant from other butyric acid-producing bacteria, includ-
ing F. nucleatum, Clostridium cochlearium, Erythema multiforme,
and Anaerococcus tetradius. F. nucleatum is commonly found in
the mouth and gut, C. cochlearium and E. multiforme in the gut,
and A. tetradius in the vagina, indicating that HDAC inhibition
caused by bacterial butyric acid may be able to reactivate HIV in










FIG 2 Interactions between multiple pathogens commonly occur at several
sites in the body. Bacteria and viruses occupying the same site can work to-
gether to enhance pathogenesis. One known mechanism by which bacteria
influence viruses is through epigenetic modifications. In HIV-positive individ-
uals, immunosuppression can increase pathogenesis of opportunistic patho-
gens. Other viruses and bacteria can contribute to AIDS progression. Several
body compartments that host polymicrobial communities are shown. The
human figure is by Mikael Haggstrom (public domain), via Wikimedia Com-
mons.
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expression were positively correlated with the amount of butyrate
produced by these bacterial species. Supernatant from F. nuclea-
tum, C. cochlearium, and A. tetradius cultures reduced binding of
HDAC1 and increased binding of RNA polymerase II (RNAPII) to
the HIV LTR. These epigenetic changes were not observed when
the culture media were heat treated to remove SCFA or when the
cells were treated with novobiocin, a topoisomerase II inhibitor
(48). NaB treatment led to increases in the activating marks
H3K4me2, H3ac, and H4ac and decreases in the repressive mark
H3K9me3 on the HIV LTR. In monocyte-derived macrophages,
HIV replication that was diminished by the integrase inhibitor
raltegravir was partially restored by the SCFAs propionic, val-
proic, and heptanoic acids (49).
Gastric cancer: H. pylori and EBV. Both present in the gut,
Helicobacter pylori and EBV have each been linked to gastric can-
cer (76, 77). Although the majority of gastric cancers are associ-
ated with H. pylori, up to 10% of gastric cancers contain EBV.
EBV-associated gastric cancers, H. pylori-associated cancers, and
coinfected cancers have different characteristics (76, 78). Cancers
with only H. pylori express Bcl-2, while coinfected or uninfected
cancers do not. In addition, c-Myc and Bax expression was de-
tected more often in H. pylori-only cancers than in coinfected ones
(78), indicating double infection may modulate disease character-
istics and possibly outcome. In addition to these two infectious
agents, increased CpG methylation has been suggested as an early
event in and risk factor for the development of gastric cancer (79,
80).
In the context of gastric cancer, H. pylori infection has been
linked to CpG hypermethylation of several tumor suppressor
genes. One gene frequently observed to be silenced by methylation
in gastric cancers is the gene coding for Runx3. Runx3 methyl-
ation has been correlated with age, tumor location, and H. pylori
infection (81). H. pylori causes methylation of Runx3 by stimulat-
ing nitric oxide production by macrophages (82). Another of
these genes is the gene coding for E-cadherin, a transmembrane
adhesion protein whose loss is involved in invasion and metastasis
(83). E-cadherin mutations have been observed in diffuse gastric
cancers, and methylation of the E-cadherin promoter may be a
second hit in patients with heterozygous mutation (84, 85).
E-cadherin methylation was associated with H. pylori infection in
patients with dyspepsia and gastric cancer, with loss of E-cadherin
protein observed by immunohistochemical staining in gastric
cancer biopsy specimens (86). Furthermore, treatment to elimi-
nate H. pylori in dyspepsia patients reversed E-cadherin methyl-
ation by 6 weeks (87). Hypermethylation of the E-cadherin and
two other tumor suppressor promoters, DAPK and p16, was
found to be increased in normal gastric mucosa of gastric cancer
patients compared to healthy controls and may be a marker for
increased risk of cancer (88). Methylation of CpG islands in p16,
LOX, FLNc, HRASLS, HAND1, THBD, and p41ARC was also
increased in H. pylori-positive individuals (89).
EBV-associated transformation and tumorigenesis in gastric
and other cancers have been linked to latency (90). Latent EBV is
highly methylated, and expression of the EBV-encoded nuclear
antigens (EBNAs) is silenced by cell-type-dependent methylation
(91, 92). However, ZEBRA, an EBV transactivator that is increased
in cells treated with P. gingivalis spent medium in association with
histone acetylation (46), preferentially binds to the methylated
form of its AP-1-like binding sites in the BRLF1 and BRRF1 pro-
moters, increasing transcription (91, 93). ZEBRA and the prod-
ucts of BRLF1 and BRRF1 are all transcription factors involved in
the switch to viral lytic replication (93). Like H. pylori, EBV has
been implicated in high levels of CpG methylation of cellular
genes associated with gastric cancer, including those coding for
p14ARF, p16INK4A, PTEN, RASSF1A, GSTP1, MGMT, and MINT2
(94–96). EBV infection was correlated with overexpression of the
DNA methyltransferase DNMT1 in gastric cancers, which was in
turn correlated with CpG methylation of the hMLH1 and THBS-1
genes (97). Given the documented effects of epigenetic modifica-
tions on EBV gene expression, the ability of EBV and gut bacteria
such as H. pylori to induce epigenetic changes in cells, and the
strong link between gastric cancer and CpG methylation, it is
plausible that coinfections may heighten gastric cancer risk.
CONCLUDING REMARKS
There is extensive evidence demonstrating the critical role of bac-
terial products in the modulation of viral epigenomes (summa-
rized in Table 1). Regardless of tumor virus type or cell type, bac-
teria are associated with enhanced viral replication, and there is
significant modulation of processes associated with epigenetic
regulation both in vitro and in vivo. In the case of latent viruses,
epigenetic modifications may lead to lytic reactivation of the virus,
production of virions, and spread of the virus. Epigenetic modifi-
cations to the promoters of virus encoded oncogenes could in-
crease production of these proteins and promote cancer progres-
sion (Fig. 1). Recent work has shown that HDAC inhibition
activity is central to bacterium-mediated activation of viral epig-
enomes, including HIV (49) and herpes group viruses (31, 46). In
addition, gut bacteria can modulate CpG methylation, an impor-
tant regulator of EBV gene expression, and the presence of all
three is a risk factor for gastric cancer (76, 77, 79, 80). These results
suggest that epigenetic modifications are common to bacterium-
mediated reactivation, but the rigorous testing needed to under-
stand the exact epigenetic mechanisms has not been done. Several
important questions remain. First, what are the mechanisms of
chromatin modification on tumor viral promoters, and are these
modifications sufficient to drive viral gene activation? Second,
what are the bacterium-mediated modifiers that deregulate the
TABLE 1 Summary of bacterium-mediated epigenetic modifications to viruses
Bacteria Virus Interaction Viral epigenetic modification(s) Reference(s)
P. gingivalis KSHV Direct Global H3 and H4 acetylation 31
EBV Direct H3 acetylation and HDAC dissociation from BZLF1 promoter 46
Periodontitis-associated bacteria HPV Indirect DNA hypomethylation 56, 57, 62–64
P. gingivalis, F. nucleatum, C. cochlearium,
E. multiforme, A. tetradius, (Butyrate)
HIV Direct Increased H3K4me2, H3ac, and H4ac, decreased H3K9me3,
RNAPII binding, HDAC1 dissociation at LTR
48, 49, 69, 70, 75
H. pylori EBV Indirect DNA hypermethylation 76, 81–97
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host antiviral response? Third, are there disease-relevant associa-
tions between bacterial infection and viral epigenetic modification
within various body cavities? Finally, do bacterium-mediated
chromatin modifications affect cellular genes that are critical to
viral pathogenesis?
There is strong evidence of enhanced pathogenesis in
bacterium-virus coinfections. Extensive use of epigenetics to di-
rect viral gene expression and emerging data on epigenetic regu-
lation of HIV and herpesviruses by bacteria suggest epigenetic
modification in polymicrobial interactions may be a generalizable
principle contributing to a wide variety of diseases. Further studies
may provide information on host and viral molecules key to dis-
ease progression that can be translated into high-impact novel
therapies that consider multiple pathogens. The treatment that
may emerge would be highly significant because of the high inci-
dence of polymicrobial diseases, particularly in immunocompro-
mised hosts. Importantly, the implications may be far-reaching, as
similar interactions may occur in all mucosally coinfected com-
partments. Without an understanding of the environmental fac-
tors that modulate these critical viral epigenetic modifications,
our ability truly to eradicate these virus-associated disorders re-
mains compromised.
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